Lamisil versus clotrimazole in the treatment of vulvovaginal candidiasis.

Authors:
Ali Zarei Mahmoudabadi
Ali Zarei Mahmoudabadi
School of Medicine
Iran
Eskandar Moghimipour
Eskandar Moghimipour
Ahvaz Jundishapur University of Medical Sciences
Iran
Zahra Seifi
Zahra Seifi
Ahvaz Jundishapur University of Medical Sciences
Iran

Iran J Microbiol 2013 Mar;5(1):86-90

Department of Medical Mycology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran ; Infectious Diseases and Tropical Medicine Centre, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Background And Objectives: Vaginal candidiasis is a common disease in women during their lifetime and occurs in diabetes patients, during pregnancy and oral contraceptives users. Although several antifungals are routinely used for treatment; however, vaginal candidiasis is a challenge for patients and gynecologists. The aim of the present study was to evaluate terbinafine (Lamisil) on Candida vaginitis versus clotrimazole.

Materials And Methods: In the present study women suspected to have vulvovaginal candidiasis were sampled and disease confirmed using direct smear and culture examination from vaginal discharge. Then, patients were randomly divided into two groups, the first group (32 cases) was treated with clotrimazole and the next (25 cases) with Lamisil. All patients were followed-up to three weeks of treatment and therapeutic effects of both antifungal were compared.

Results: Our results shows that 12 (37.5%) patients were completely treated with clotrimazole during two weeks and, 6(18.8%) patients did not respond to drugs and were refereed for fluconazole therapy. Fourteen (43.8%) patients showed moderate response and clotrimazole therapy was extended for one more week. When Lamisil was administrated, 19 (76.0%) patients were completely treated with Lamisil in two weeks, and 1 (4.0%) of the patients did not respond to the drug and was refereed for fluconazole therapy. Five (20.0%) of our patients showed moderate response and Lamisil therapy was extended for one more week.

Conclusion: Our results show that vaginal cream, 1% Lamisil, could be suggested as a first-line treatment in vulvovaginal candidiasis.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3577561PMC
March 2013
128 Reads

Publication Analysis

Top Keywords

vulvovaginal candidiasis
12
patients
10
vaginal candidiasis
8
patients respond
8
patients moderate
8
completely treated
8
treatment vulvovaginal
8
therapy extended
8
fluconazole therapy
8
moderate response
8
refereed fluconazole
8
patients completely
8
treated clotrimazole
8
lamisil
7
candidiasis
5
culture examination
4
week lamisil
4
examination vaginal
4
extended week
4
randomly divided
4

Similar Publications

Comparative study of fluconazole and clotrimazole for the treatment of vulvovaginal candidiasis.

Sex Transm Dis 1995 Jul-Aug;22(4):228-30

Department of Obstetrics and Gynecology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

Background: The introduction of the triazole antifungal agent fluconazole, which can be used via an oral route and single dose, has had a significant impact on patient compliance.

Goal Of This Study: To compare the efficacy and safety of a single oral dose of 150 mg fluconazole with that of a 100-mg clotrimazole vaginal suppository twice a day in the morning and at bedtime for 3 days in the treatment of vulvovaginal candidiasis.

Study Design: A single-blind, randomized controlled trial was conducted at Ramathibodi Hospital between June 1 and September 30, 1993. Read More

View Article
November 1995

Guideline: vulvovaginal candidosis (AWMF 015/072), S2k (excluding chronic mucocutaneous candidosis).

Mycoses 2015 Mar;58 Suppl 1:1-15

Deutsches Zentrum für Infektionen in Gynäkologie und Geburtshilfe, Vogelsangstrasse 106, 42109 Wuppertal, Germany.

The oestrogenised vagina is colonised by Candida species in at least 20% of women; in late pregnancy and in immunosuppressed patients, this increases to at least 30%. In most cases, Candida albicans is involved. Host factors, particularly local defence mechanisms, gene polymorphisms, allergies, serum glucose levels, antibiotics, psycho-social stress and oestrogens influence the risk of candidal vulvovaginitis. Read More

View Article
March 2015

The Comparison of vaginal cream of mixing yogurt, honey and clotrimazole on symptoms of vaginal candidiasis.

Glob J Health Sci 2015 Apr 3;7(6):108-16. Epub 2015 Apr 3.

Department of Midwifery, Faculty of Nursing & Midwifery, Iran University of Medical Sciences, Tehran, Iran.

Background: Vulvovaginal candidiasis is known as one of the most common fungal infection among women of reproductive age and considered as an important public health problem. In recent years, due to resistance to common antifungal medication, the use of traditional medicine of anti-fungal and herbal treatment increased. Therefore the objective of this study was to determine the effects of vaginal cream, mixture of yogurt and honey and comparing it with clotrimazole vaginal cream on symptoms of Vulvovaginal candidiasis in patients. Read More

View Article
April 2015

The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis.

Authors:
I W Fong

Genitourin Med 1992 Dec;68(6):374-7

Department of Medicine, St Michael's Hospital, University of Toronto, Ontario, Canada.

Objective: To determine the comparative efficacy of oral itraconazole versus intravaginal clotrimazole in suppressing recurrent episodes of vulvovaginal candidiasis.

Design: Prospective randomised open study of women with recurrent vulvovaginal candidiasis. Clinical and microbiological assessments were made monthly for 12 months. Read More

View Article
December 1992